Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy
Frontiers in Pharmacology · 07.01.2025 · 15
DOI: 10.3389/fphar.2024.1505768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.01.2025. Verfasst von Zhuomiao Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Non-alcoholic steatohepatitis (NASH) is a progressive liver disease with lipid accumulation, inflammation, and liver fibrosis. Ponatinib, a third-generation tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, was found to improve metabolic disorders in mice. However, the role of ponatinib in liver inflammation and fibrosis remains to be elucidated. Here we aimed to determine the effect of ponatinib in non-alcoholic steatohepatitis.
Methods
We explored the function and mechanism of ponatinib using a mouse model of NASH induced by a methionine and choline deficient (MCD) diet and LO2 cells cultured in MCD mimic medium.
Results
Here, we found that ponatinib reduced liver lipid deposition, fibrosis, and inflammation induced by MCD diet without affecting body weight and blood glucose. Meanwhile, we found that ponatinib attenuated steatohepatitis and inflammation in LO2 cells induced by MCD mimic medium. We further discovered that the expression levels of LC3II and lysosomal associated membrane protein 1 (LAMP1) were reduced and the expression level of p62 was upregulated in both mouse and cell models, suggesting that autophagy was inhibited, which was restored by ponatinib treatment. In addition, transcription factor EB (TFEB) is a major regulator of autophagy and lysosome biogenesis and the transcription and protein expression levels of TFEB were decreased in steatosis hepatocytes, which could be ameliorated by ponatinib treatment.
Conclusion
These results revealed that the beneficial effects of ponatinib on NASH via TFEB-mediated autophagy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China.
- Joint Shantou International Eye Center, Shantou University and The Chinese University of Hong Kong, Shantou, China.
- Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
- Department of Orthopaedics and Traumatology, The Seventh Affiliated Hospital, Southern Medical University, Foshan, China.
Zitieren
APA
Lin, Z., Yang, M., Yu, X., Tan, G., & Zhong, J. (2025). Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1505768
Vancouver
Lin Z, Yang M, Yu X, Tan G, Zhong J. Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy. Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1505768
BibTeX
@article{Lin2025,
author = {Lin, Zhuomiao and Yang, Meiqing and Yu, Xihui and Tan, Guozhu and Zhong, Jiahong},
title = {Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {15},
doi = {10.3389/fphar.2024.1505768}
}
EUVIMED